Marker Therapeutics, Inc. (NASDAQ:MRKR) Short Interest Down 35.5% in February

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a large decline in short interest during the month of February. As of February 15th, there was short interest totalling 149,800 shares, a decline of 35.5% from the January 31st total of 232,100 shares. Based on an average daily trading volume, of 77,600 shares, the short-interest ratio is presently 1.9 days. Approximately 2.1% of the shares of the stock are short sold.

Insider Buying and Selling

In other news, Director Steve Elms acquired 11,085 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were bought at an average cost of $3.20 per share, for a total transaction of $35,472.00. Following the acquisition, the director now owns 325,370 shares in the company, valued at approximately $1,041,184. This represents a 3.53 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Enterprise Associates 16 New acquired 554,250 shares of the stock in a transaction that occurred on Monday, December 23rd. The stock was purchased at an average price of $3.20 per share, for a total transaction of $1,773,600.00. Following the completion of the acquisition, the insider now owns 1,625,678 shares in the company, valued at $5,202,169.60. The trade was a 51.73 % increase in their position. The disclosure for this purchase can be found here. 14.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MRKR. Millennium Management LLC purchased a new position in Marker Therapeutics in the 4th quarter worth approximately $50,000. Invst LLC purchased a new position in Marker Therapeutics in the 3rd quarter worth approximately $56,000. Northern Trust Corp lifted its stake in Marker Therapeutics by 66.9% in the 4th quarter. Northern Trust Corp now owns 54,156 shares of the company’s stock worth $168,000 after purchasing an additional 21,703 shares in the last quarter. LPL Financial LLC purchased a new position in Marker Therapeutics in the 4th quarter worth approximately $248,000. Finally, Aisling Capital Management LP raised its position in shares of Marker Therapeutics by 3.5% during the 4th quarter. Aisling Capital Management LP now owns 325,370 shares of the company’s stock valued at $1,012,000 after buying an additional 11,084 shares during the period. 22.39% of the stock is owned by hedge funds and other institutional investors.

Marker Therapeutics Trading Down 5.2 %

MRKR traded down $0.08 during trading on Monday, reaching $1.45. The company’s stock had a trading volume of 17,560 shares, compared to its average volume of 71,691. The firm has a fifty day simple moving average of $2.26 and a two-hundred day simple moving average of $3.00. Marker Therapeutics has a 1 year low of $1.44 and a 1 year high of $5.99.

Wall Street Analyst Weigh In

Separately, Brookline Capital Management raised shares of Marker Therapeutics to a “strong-buy” rating in a research note on Monday, February 10th.

About Marker Therapeutics

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.